---
title: "TUS-PHARMA: Expected net profit loss of RMB 19 million to RMB 15 million in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248384273.md"
description: "TUS-PHARMA expects a net loss of RMB 19 million to RMB 15 million in the first half of 2025, an improvement compared to the loss of RMB 23.3946 million in the same period last year. The net profit after deducting non-recurring gains and losses is expected to be a loss of RMB 25 million to RMB 20 million, with basic earnings per share loss of RMB 0.0793 to RMB 0.0626. The company's total operating revenue decline and the rise in the prices of raw and auxiliary materials have affected the overall gross margin and profitability"
datetime: "2025-07-14T09:30:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248384273.md)
  - [en](https://longbridge.com/en/news/248384273.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248384273.md)
generator: "portal-rs"
---

# TUS-PHARMA: Expected net profit loss of RMB 19 million to RMB 15 million in the first half of 2025

TUS-PHARMA announced that it expects the net profit attributable to shareholders of the listed company for the period from January 1, 2025, to June 30, 2025, to be a loss of 19 million to 15 million yuan, compared to a loss of 23.3946 million yuan in the same period last year; the net profit after deducting non-recurring gains and losses is expected to be a loss of 25 million to 20 million yuan, compared to a loss of 24.389 million yuan in the same period last year; the basic earnings per share is expected to be a loss of 0.0793 yuan/share to 0.0626 yuan/share, compared to a loss of 0.0977 yuan/share in the same period last year. The company's total operating revenue has declined in the past two years due to factors such as market environment, and the prices of some raw and auxiliary materials have risen, leading to a decrease in overall gross profit margin and profitability

### Related Stocks

- [000590.CN](https://longbridge.com/en/quote/000590.CN.md)

## Related News & Research

- [Cho Kwang Sik, Related Parties Raise PNC Technologies Stake to 47.18% From 38.07%](https://longbridge.com/en/news/305620649.md)
- [EvoNext releases Ascend Sport Technology audited accounts ahead of merger](https://longbridge.com/en/news/305620792.md)
- [CLSA: Z.AI 's Coding Capability Combined With Self-Improvement Supports AI Growth](https://longbridge.com/en/news/305619610.md)
- [BELRISE: Manufacturing-led growth and expanding assembly, electronics and aerospace wins underpin unchanged guidance](https://longbridge.com/en/news/305620691.md)
- [TA Securities deems Epicon's RM 543.16 million acquisitions fair](https://longbridge.com/en/news/305620644.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**